Skip to content

Study · Not a test of the peptide alone · 2005

3 results

Measurement of vasoactive intestinal peptide using a competitive fluorescent microsphere immunoassay or ELISA in human blood samples.

Song EY, VanDunk C, Kuddo T, Nelson PG

Journal of immunological methods25 Apr 2005Cited by 8 (Europe PMC)

PMID15894328 (opens in a new tab)DOI10.1016/j.jim.2005.02.009 (opens in a new tab)PepBankPUB-15894328
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneOther designOther

    The competitive fluorescent microsphere immunoassay detected VIP with a sensitivity of 2.5 pg/ml, against 20.0 pg/ml for an ELISA.

    In plain wordsA new lab test for VIP in blood could detect lower amounts of VIP than a standard ELISA test.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableSensitivity of cFMI versus ELISA for VIP
    Study

    humann: not reported in source

    human serum, plasma and dried blood spot eluates
    Comparator
    ELISA
    Outcome group
    Analytical methods and detection · Pharmacology

    Measurements

    Sensitivity
    2.5 pg/ml
    cFMI
    Sensitivity
    20 pg/ml
    ELISA

    Source sentences

    Summary
    This newly developed cFMI was more sensitive (2.5 vs. 20.0 pg/ml)
    1 context sentence
    Summary · context
    In this study, we have developed a "Competitive Fluorescent Microsphere Immunoassay" (cFMI) in which VIP competes with biotinylated VIP in binding to polyclonal antibodies on microspheres.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneOther designOther

    The competitive fluorescent microsphere immunoassay was more reproducible than the ELISA for measuring VIP.

    In plain wordsA new lab test for VIP in blood gave more repeatable results than a standard ELISA test.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableReproducibility of cFMI versus ELISA for VIP
    Study

    humann: not reported in source

    human serum, plasma and dried blood spot eluates
    Comparator
    ELISA
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    This newly developed cFMI was more sensitive (2.5 vs. 20.0 pg/ml), and more reproducible than the ELISA.
    1 context sentence
    Summary · context
    In this study, we have developed a "Competitive Fluorescent Microsphere Immunoassay" (cFMI) in which VIP competes with biotinylated VIP in binding to polyclonal antibodies on microspheres.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneOther designOther

    VIP concentrations in serum, plasma and dried blood spot eluates measured by the cFMI were similar to those measured by ELISA.

    In plain wordsThe new lab test and the standard ELISA test gave similar VIP levels in blood samples.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP concentrations measured by cFMI versus ELISA
    Study

    humann: not reported in source

    human serum, plasma and dried blood spot eluates
    Comparator
    ELISA
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    We have determined that the VIP concentrations of serum, plasma, and dried blood spot eluate specimens as measured with the cFMI assay system were similar to those measured with ELISA.
    1 context sentence
    Summary · context
    In this study, we have developed a "Competitive Fluorescent Microsphere Immunoassay" (cFMI) in which VIP competes with biotinylated VIP in binding to polyclonal antibodies on microspheres.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.